185 related articles for article (PubMed ID: 32245899)
1. Molecular Imaging of Bone Metastases and Their Response to Therapy.
Cook GJR; Goh V
J Nucl Med; 2020 Jun; 61(6):799-806. PubMed ID: 32245899
[TBL] [Abstract][Full Text] [Related]
2. Functional and Hybrid Imaging of Bone Metastases.
Cook GJ; Goh V
J Bone Miner Res; 2018 Jun; 33(6):961-972. PubMed ID: 29665140
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. A Prospective Study Comparing
Löfgren J; Mortensen J; Rasmussen SH; Madsen C; Loft A; Hansen AE; Oturai P; Jensen KE; Mørk ML; Reichkendler M; Højgaard L; Fischer BM
J Nucl Med; 2017 Nov; 58(11):1778-1785. PubMed ID: 28798033
[TBL] [Abstract][Full Text] [Related]
5. What Is the Comparative Ability of 18F-FDG PET/CT, 99mTc-MDP Skeletal Scintigraphy, and Whole-body MRI as a Staging Investigation to Detect Skeletal Metastases in Patients with Osteosarcoma and Ewing Sarcoma?
Aryal A; Kumar VS; Shamim SA; Gamanagatti S; Khan SA
Clin Orthop Relat Res; 2021 Aug; 479(8):1768-1779. PubMed ID: 33635285
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic bone imaging in patients with prostate cancer: patient experience and acceptance of NaF-PET/CT, choline-PET/CT, whole-body MRI, and bone SPECT/CT.
Dyrberg E; Larsen EL; Hendel HW; Thomsen HS
Acta Radiol; 2018 Sep; 59(9):1119-1125. PubMed ID: 29313360
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic performance of
Ishiguchi H; Ito S; Kato K; Sakurai Y; Kawai H; Fujita N; Abe S; Narita A; Nishio N; Muramatsu H; Takahashi Y; Naganawa S
Ann Nucl Med; 2018 Jun; 32(5):348-362. PubMed ID: 29667143
[TBL] [Abstract][Full Text] [Related]
8. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M
Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330
[TBL] [Abstract][Full Text] [Related]
9. Imaging Bone Metastases in Breast Cancer: Staging and Response Assessment.
Cook GJ; Azad GK; Goh V
J Nucl Med; 2016 Feb; 57 Suppl 1():27S-33S. PubMed ID: 26834098
[TBL] [Abstract][Full Text] [Related]
10. Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer.
Hahn S; Heusner T; Kümmel S; Köninger A; Nagarajah J; Müller S; Boy C; Forsting M; Bockisch A; Antoch G; Stahl A
Acta Radiol; 2011 Nov; 52(9):1009-14. PubMed ID: 21969709
[TBL] [Abstract][Full Text] [Related]
11. SPECT/CT, PET/CT, and PET/MRI for Response Assessment of Bone Metastases.
Zamani-Siahkali N; Mirshahvalad SA; Farbod A; Divband G; Pirich C; Veit-Haibach P; Cook G; Beheshti M
Semin Nucl Med; 2024 May; 54(3):356-370. PubMed ID: 38172001
[TBL] [Abstract][Full Text] [Related]
12. Assessment of whole-body MRI including diffusion-weighted sequences in the initial staging of breast cancer patients at high risk of metastases in comparison with PET-CT: a prospective cohort study.
Hottat NA; Badr DA; Ben Ghanem M; Besse-Hammer T; Lecomte SM; Vansteelandt C; Lecomte SL; Khaled C; De Grove V; Salem Wehbe G; Cannie MM; Jani JC
Eur Radiol; 2024 Jan; 34(1):165-178. PubMed ID: 37555959
[TBL] [Abstract][Full Text] [Related]
13. A Prospective Comparison of
Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
[TBL] [Abstract][Full Text] [Related]
14. Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma.
Mosavi F; Johansson S; Sandberg DT; Turesson I; Sörensen J; Ahlström H
AJR Am J Roentgenol; 2012 Nov; 199(5):1114-20. PubMed ID: 23096187
[TBL] [Abstract][Full Text] [Related]
15. Prospective comparison of the diagnostic accuracy of 18F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients.
Bruckmann NM; Kirchner J; Umutlu L; Fendler WP; Seifert R; Herrmann K; Bittner AK; Hoffmann O; Mohrmann S; Antke C; Schimmöller L; Ingenwerth M; Breuckmann K; Stang A; Buchbender C; Antoch G; Sawicki LM
Eur Radiol; 2021 Nov; 31(11):8714-8724. PubMed ID: 33912991
[TBL] [Abstract][Full Text] [Related]
16. Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan?
Caglar M; Kupik O; Karabulut E; Høilund-Carlsen PF
Rev Esp Med Nucl Imagen Mol; 2016; 35(1):3-11. PubMed ID: 26514321
[TBL] [Abstract][Full Text] [Related]
17. Single photon emission computed tomography (SPECT) and SPECT/low-dose computerized tomography did not increase sensitivity or specificity compared to planar bone scintigraphy for detection of bone metastases in advanced breast cancer.
Haraldsen A; Bluhme H; Røhl L; Pedersen EM; Jensen AB; Hansen EB; Nellemann H; Rasmussen F; Morsing A
Clin Physiol Funct Imaging; 2016 Jan; 36(1):40-6. PubMed ID: 25257661
[TBL] [Abstract][Full Text] [Related]
18. Does whole-body bone SPECT/CT provide additional diagnostic information over [18F]-FCH PET/CT for the detection of bone metastases in the setting of prostate cancer biochemical recurrence?
de Leiris N; Leenhardt J; Boussat B; Montemagno C; Seiller A; Phan Sy O; Roux J; Laramas M; Verry C; Iriart C; Fiard G; Long JA; Descotes JL; Vuillez JP; Riou L; Djaileb L
Cancer Imaging; 2020 Aug; 20(1):58. PubMed ID: 32787923
[TBL] [Abstract][Full Text] [Related]
19. Molecular and Functional Imaging of Bone Metastases in Breast and Prostate Cancers: An Overview.
Azad GK; Taylor B; Rubello D; Colletti PM; Goh V; Cook GJ
Clin Nucl Med; 2016 Jan; 41(1):e44-50. PubMed ID: 26402127
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic Significance of 18F-FDG PET/CT Imaging Coupled with Magnetic Resonance Imaging of the Entire Body for Bone Metastases.
Guo H; Zhang Z; Wang L; Yao S; Xu S; Ma S; Liu S
Contrast Media Mol Imaging; 2022; 2022():7717398. PubMed ID: 36247843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
